ArticleTherapeutic advances in medical oncology2025

The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models.

Dongli Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.